Compare Stocks → New York goes dark, then America. (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DFFNOTCMKTS:MCUJFNASDAQ:NVLNOTCMKTS:NVLNFNASDAQ:TLGT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsMCUJFMedicure$0.74-6.3%$0.85$0.74▼$1.26$7.72M0.92874 shs12,400 shsNVLNNovelion Therapeutics$0.70$0.54▼$2.35$13.77M2.12190,529 shs26,947 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%-37.59%MCUJFMedicure-6.89%-3.07%-6.30%-22.21%-25.30%NVLNNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%TLGTTeligent0.00%0.00%0.00%0.00%0.00%New York goes dark, then America. (Ad)Artificial intelligence is about to trigger a shocking new crisis in New York. Experts warn it could be “the next 9/11” and while New York will be ground zero for this looming catastrophe, it will not be the only state impacted. This crisis could affect 233 million Americans starting at any moment from now. Click here for the full story.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AMCUJFMedicure$16.07M0.48$0.08 per share8.96$1.41 per share0.52NVLNNovelion Therapeutics$130.43M0.00N/AN/A($4.69) per share0.00NVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15TLGTTeligentN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDFFNDiffusion Pharmaceuticals-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/AMCUJFMedicure-$680K-$0.06N/A∞N/A-4.17%-4.29%-3.14%5/24/2024 (Estimated)NVLNNovelion Therapeutics-$108.33MN/A0.00N/AN/A-79.43%N/A-26.13%N/ANVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/ATLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest TLGT, NVLNF, MCUJF, NVLN, and DFFN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2024Q4 2023MCUJFMedicureN/A-$0.10-$0.10-$0.10N/A$3.73 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/ANVLNNovelion TherapeuticsN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDFFNDiffusion PharmaceuticalsN/A10.7110.71MCUJFMedicure0.011.921.55NVLNNovelion TherapeuticsN/A0.240.21NVLNFNovelion TherapeuticsN/AN/AN/ATLGTTeligentN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipDFFNDiffusion Pharmaceuticals9.95%MCUJFMedicureN/ANVLNNovelion Therapeutics35.00%NVLNFNovelion Therapeutics48.64%TLGTTeligentN/AInsider OwnershipCompanyInsider OwnershipDFFNDiffusion Pharmaceuticals1.80%MCUJFMedicure12.90%NVLNNovelion Therapeutics3.60%NVLNFNovelion Therapeutics3.60%TLGTTeligent0.17%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableNVLNNovelion Therapeutics10919.62 millionN/AOptionableNVLNFNovelion Therapeutics10919.62 millionN/ANot OptionableTLGTTeligent2,357N/AN/AOptionableTLGT, NVLNF, MCUJF, NVLN, and DFFN HeadlinesSourceHeadlineTopical pain reliever recalled for problem that can cause ‘severe morbidity, even death’charlotteobserver.com - June 7 at 10:18 AMβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzznews.google.com - May 13 at 1:32 AMLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan Newsnews.google.com - May 13 at 1:32 AMGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Todaynews.google.com - May 11 at 4:41 AMGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examinernews.google.com - May 8 at 10:54 AMDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journalnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examinernews.google.com - May 5 at 9:12 AMEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journalnews.google.com - May 3 at 7:08 AMErythromycin Market with Focus on Growth Analysis, Production ... - Digital Journalnews.google.com - May 2 at 8:42 AMFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journalnews.google.com - April 29 at 8:17 AMTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRnews.google.com - April 28 at 10:17 PMDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRnews.google.com - April 26 at 1:32 PMTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRnews.google.com - April 26 at 8:32 AMTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan Newsnews.google.com - April 24 at 4:23 PMIDT Corp. Cl Bwsj.com - April 23 at 2:59 AMMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journalnews.google.com - April 17 at 2:17 PMHikma Names Injectables Chief Mishlawi As CEO - Generics Bulletinnews.google.com - April 12 at 1:13 PMMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journalnews.google.com - April 10 at 1:16 PMEverstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globenews.google.com - April 6 at 1:58 PMLidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journalnews.google.com - March 29 at 7:08 AMMobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journalnews.google.com - March 29 at 2:07 AMGonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPRnews.google.com - March 28 at 10:26 AMBankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD Supranews.google.com - March 25 at 8:59 AMMedia Sentiment Over TimeCompany DescriptionsDiffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.MedicureOTCMKTS:MCUJFMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Novelion TherapeuticsNASDAQ:NVLNNovelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Novelion TherapeuticsOTCMKTS:NVLNFNovelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.TeligentNASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.